Completed OBSERVATIONAL NCT01850966

Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis

Sponsor: Eisai Co., Ltd.

Interventions Iguratimod

Updated 11 times since 2017 Last updated: Nov 2, 2018 Started: Sep 12, 2012 Primary completion: Apr 13, 2014 Completion: Apr 13, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01850966, this observational or N/A phase trial focuses on Rheumatoid Arthritis and remains completed. Sponsored by Eisai Co., Ltd., it has been updated 11 times since 2012, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Dec 2018 — Jan 2021 [monthly]

Completed

▶ Show 6 earlier versions

Oct 2018 — Dec 2018 [monthly]

Completed
Sep 2018 — Oct 2018 [monthly]

Completed
Jun 2018 — Sep 2018 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Mar 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Mar 2017 [monthly]

Completed NA

First recorded

Sep 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eisai Co., Ltd.

Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abashiri, Japan , Abiko, Japan , Adachi City, Japan , Agatsuma, Japan , Agawa, Japan , Aisai, Japan , Aizu-Wakamatsu, Japan , Aki, Japan , Aki-takata, Japan , Akiruno, Japan and 436 more locations